Christopher Martin, MD
Child & Adolescent Psychiatry · Amherst, NYNPI 1134122955
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,880, 2.4 times the $792 reported in 2019. Among child & adolescent psychiatry clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$693
- Alkermes, Inc.$597
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$458
- Vanda Pharmaceuticals Inc.$404
- Johnson & Johnson$394
- Lundbeck LLC$359
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,180100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 39 | $693 |
| Alkermes, Inc. | 26 | $597 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $458 |
| Vanda Pharmaceuticals Inc. | 17 | $404 |
| Johnson & Johnson | 42 | $394 |
| Lundbeck LLC | 22 | $359 |
| Sunovion Pharmaceuticals Inc. | 26 | $340 |
| Supernus Pharmaceuticals, Inc. | 13 | $318 |
| Neurocrine Biosciences, Inc. | 9 | $251 |
| Bausch Health US, LLC | 10 | $197 |
| Teva Pharmaceuticals USA, Inc. | 7 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $155 |
| Collegium Pharmaceutical, Inc. | 7 | $129 |
| Axsome Therapeutics, Inc. | 5 | $128 |
| Corium, LLC | 6 | $106 |
| Jazz Pharmaceuticals Inc. | 4 | $84 |
| AbbVie | 4 | $67 |
| Tris Pharma Inc | 4 | $62 |
| Eisai Inc. | 3 | $50 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Biogen | 1 | $29 |
| Neos Therapeutics, LP | 2 | $24 |
| Neuronetics, Inc. | 2 | $23 |
| Shire North American Group Inc | 1 | $22 |
| Almatica Pharma LLC | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Merck | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$5,180 in reported general payments places this provider in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Wellbutrin XlBupropion Hcl | 21 | $57,940 |
| RexultiBrexpiprazole | 13 | $17,078 |
| TrintellixVortioxetine Hydrobromide | 28 | $14,618 |
| DayvigoLemborexant | 14 | $4,510 |
| Aripiprazole | 69 | $4,385 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $4,346 |
| Lisdexamfetamine Dimesylate | 15 | $4,101 |
| Bupropion XlBupropion Hcl | 112 | $3,511 |
| Buspirone Hcl | 132 | $2,157 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 41 | $2,065 |
| Haloperidol | 12 | $1,827 |
| Clonazepam | 116 | $1,668 |
| Atomoxetine Hcl | 11 | $1,610 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 58 | $1,444 |
| Alprazolam | 111 | $1,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $693 | $17,07813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $155 | $14,61828 claims |
| Eisai Inc.Dayvigo | $50 | $4,51014 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $848107 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 child & adolescent psychiatry providers in New York.
Other child & adolescent psychiatry in Amherst
- Matthew LorberNew York$398K
- Mitchell CabisudoNew Windsor$346K
- Parinda ParikhWhite Plains$185K
- Jeffrey NewcornNew York$165K
- John MarinoCanandaigua$70K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Vijay PampanaMiddletown$19K
- Marc ReitmanHuntington$13K
- Marie CharlesBrooklyn$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.